SCHEMBL22967393

SCHEMBL22967393

CCOc1ccc(OCc2ccccn2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
KDM4E B2RXH2 3/20 0.63
PARP10 Q53GL7 1/20 0.59
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
HPGD P15428 2/20 0.58
TSHR P16473 1/20 0.58
MAPK1 P28482 1/20 0.58
CASP3 P42574 1/20 0.58
SENP8 Q96LD8 1/20 0.58
SENP7 Q9BQF6 1/20 0.58
SENP6 Q9GZR1 1/20 0.58
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
NQO1 P15559 1/20 0.52
SYK P43405 4/20 0.51
AURKB Q96GD4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12310925 0.86 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2KDM4EPARP10NPC1
SCHEMBL1073540 0.85 SYK (0.68) ALDH1A1SMN1; SMN2KDM4EPARP10NPC1
SCHEMBL169753 0.85 SMN1; SMN2 (0.63) ALDH1A1SMN1; SMN2KDM4EPARP10NPC1
Ammonia Solution, Strong SCHEMBL23291159 0.84 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2KDM4EPARP10NPC1
SCHEMBL6445371 0.84 KCNH2 (0.67) ALDH1A1SMN1; SMN2KDM4EPARP10NPC1
SCHEMBL22874534 0.83 PARP10 (0.66) ALDH1A1SMN1; SMN2KDM4EPARP10NPC1
SCHEMBL16093378 0.83 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2KDM4EPARP10NPC1
SCHEMBL22967626 0.82 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2KDM4EPARP10NPC1
SCHEMBL21568937 0.81 KDM4E (0.63) ALDH1A1SMN1; SMN2KDM4EPARP10NPC1
SCHEMBL10388636 0.81 KDM4E (0.63) ALDH1A1SMN1; SMN2KDM4EPARP10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-10 US disclosed
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF ACCSALUS BIOSCIENCES LIMITED (VG) 2021-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548900-B2 Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof WNK1, WNK2, WNK3 ALDH1A1 1467/4885SMN1; SMN2 3866/4885KDM4E 2166/4885
US-20210040114-A1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF WNK1, WNK2, WNK3 ALDH1A1 1467/4885SMN1; SMN2 3866/4885KDM4E 2166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.